Tirzepatide is associated with a much lower all-cause mortality rate than semaglutide when patients present with Type 2 diabetes, chronic kidney disease (CKD) and heart failure, according to new data presented at the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI).
The study’s authors noted that patients with Type 2 diabetes often go on to develop CKD and/or heart failure due to the close relationships of those conditions. To learn more about the best possible treatment for these conditions, the group examined data from more than 9,000 patients who all presented with Type 2 diabetes, CKS and heart failure. While 4,856 patients were treated semaglutide, another 4,856 were treated with tirzepatide. All patients were followed for a full year.
Overall, semaglutide was linked to a higher one-year risk of all-cause mortality, acute myocardial infarction, ischemic stroke and hospital readmission than tirzepatide. The rates of hemorrhagic stroke, atrial fibrillation, atrial flutter and cardiac arrest were comparable between the two drugs. However, HbA1c levels were less likely to be under 7% for patients treated with tirzepatide than those treated with semaglutide.
Tirzepatide is sold under the brand names Mounjaro and Zepbound. Semaglutide is sold under the brand names Ozempic and Wegovy
To find out more, CLICK HERE.
